FDA record · warning letter

FDA warning letter: ProRx LLC (Apr 7, 2026)

On Apr 7, 2026, FDA issued a warning letter to ProRx LLC of Exton, PA under the subject "Compounding Pharmacy/Adulterated Drug Products". It names semaglutide, tirzepatide. Open: no closeout letter published as of Oct 3, 2026.

Julian CaraulaniFounder, PriceTracker GLP-1FDA record read Oct 3

Status: Open: no closeout letter published as of Oct 3, 2026.

What FDA’s record states

FDA record for the warning letter to ProRx LLC
Field	What FDA’s record states	Source
Recipient	ProRx LLC	FDA letter
Location	Exton, PA	FDA letter
Letter date	Apr 7, 2026	FDA letter
Posted by FDA	May 12, 2026	FDA index
Issuing office	Center for Drug Evaluation and Research (CDER)	FDA letter
Subject	Compounding Pharmacy/Adulterated Drug Products	FDA letter
MARCS-CMS number	723704	FDA letter
GLP-1 drugs named	Semaglutide, Tirzepatide	FDA letter
Response letter	Not published by FDA	FDA letter
Closeout letter	Not published by FDA	FDA letter

“FDA also acknowledges that, on October 15, 2025, your firm initiated a voluntary recall of Lot PRORX08062025-3 of Tirzepatide Injection 27mg/3mL, 3mL in multidose vials and various lots of Semaglutide Injection multidose vials in multiple strengths, within expiry, due to a lack of sterility assurance.”FDA warning letter to ProRx LLC, Apr 7, 2026 · read the full letter on fda.gov ↗

What this is and is not.A warning letter is FDA’s statement of what it considers significant violations. It is an allegation, not a court finding, and the firm can respond. A closeout letter is posted when FDA confirms the violations were corrected.

Source

Every field above is copied from FDA’s page for this letter, read Oct 3, 2026. The letter on fda.gov ↗ · All 161 GLP-1 warning letters